CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
Pestalozzi, Bernhard C, Prof, Holmes, Eileen, PhD, de Azambuja, Evandro, MD, Metzger-Filho, Otto, MD, Hogge, Laurence, MSc, Scullion, Matt, PhD, Láng, István, Prof, Wardley, Andrew, MD, Lichinitser, Mikhail, MD, Sanchez, Roberto I Lopez, MD, Müller, Volkmar, Prof, Dodwell, David, MD, Gelber, Richard D, Prof, Piccart-Gebhart, Martine J, Prof, Cameron, David, Prof
Published in The lancet oncology (01.03.2013)
Published in The lancet oncology (01.03.2013)
Get full text
Journal Article
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Zielinski, Christoph, Prof, Láng, István, Prof, Inbar, Moshe, Prof, Kahán, Zsuzsanna, Prof, Greil, Richard, Prof, Beslija, Semir, Prof, Stemmer, Salomon M, MD, Zvirbule, Zanete, MD, Steger, Günther G, MD, Melichar, Bohuslav, Prof, Pienkowski, Tadeusz, MD, Sirbu, Daniela, MD, Petruzelka, Luboš, Prof, Eniu, Alexandru, MD, Nisenbaum, Bella, MD, Dank, Magdalena, Prof, Anghel, Rodica, Prof, Messinger, Diethelm, MSc, Brodowicz, Thomas, MD
Published in The lancet oncology (01.09.2016)
Published in The lancet oncology (01.09.2016)
Get full text
Journal Article
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
von Minckwitz, Gunter, Prof, Puglisi, Fabio, MD, Cortes, Javier, MD, Vrdoljak, Eduard, Prof, Marschner, Norbert, MD, Zielinski, Christoph, Prof, Villanueva, Cristian, MD, Romieu, Gilles, MD, Lang, István, Prof, Ciruelos, Eva, MD, De Laurentiis, Michele, MD, Veyret, Corinne, Prof, de Ducla, Sabine, DEA, Freudensprung, Ulrich, MSc, Srock, Stefanie, MD, Gligorov, Joseph, MD
Published in The lancet oncology (01.10.2014)
Published in The lancet oncology (01.10.2014)
Get full text
Journal Article
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
André, Fabrice, Prof, O'Regan, Ruth, Prof, Ozguroglu, Mustafa, Prof, Toi, Masakazu, Prof, Xu, Binghe, Prof, Jerusalem, Guy, Prof, Masuda, Norikazu, MD, Wilks, Sharon, MD, Arena, Francis, MD, Isaacs, Claudine, Prof, Yap, Yoon-Sim, MD, Papai, Zsuzsanna, MD, Lang, Istvan, Prof, Armstrong, Anne, MD, Lerzo, Guillermo, MD, White, Michelle, MD, Shen, Kunwei, Prof, Litton, Jennifer, MD, Chen, David, PhD, Zhang, Yufen, PhD, Ali, Shyanne, Taran, Tetiana, MD, Gianni, Luca, Dr
Published in The lancet oncology (01.05.2014)
Published in The lancet oncology (01.05.2014)
Get full text
Journal Article
Web Resource
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
Lang, Istvan, Prof, Brodowicz, Thomas, MD, Ryvo, Larisa, MD, Kahan, Zsuzsanna, Prof, Greil, Richard, Prof, Beslija, Semir, MD, Stemmer, Salomon M, MD, Kaufman, Bella, MD, Zvirbule, Zanete, MD, Steger, Günther G, MD, Melichar, Bohuslav, Prof, Pienkowski, Tadeusz, MD, Sirbu, Daniela, MD, Messinger, Diethelm, MSc, Zielinski, Christoph, Prof
Published in The lancet oncology (01.02.2013)
Published in The lancet oncology (01.02.2013)
Get full text
Journal Article
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
Martin, Miguel, Prof, Roche, Henri, Prof, Pinter, Tamas, MD, Crown, John, Prof, Kennedy, M John, MB, Provencher, Louise, MD, Priou, Frank, MD, Eiermann, Wolfgang, Prof, Adrover, Encarna, MD, Lang, Istvan, Prof, Ramos, Manuel, MD, Latreille, Jean, FRCPC, Jagiełło-Gruszfeld, Agnieszka, MD, Pienkowski, Tadeusz, MD, Alba, Emilio, MD, Snyder, Raymond, MMed, Almel, Sachin, MD, Rolski, Janusz, MD, Munoz, Montserrat, MD, Moroose, Rebecca, MD, Hurvitz, Sara, MD, Baños, Ana, BSc, Adewoye, Henry, MD, Hei, Yong-Jiang, MD, Lindsay, Mary-Ann, PhD, Rupin, Matthieu, MSc, Cabaribere, David, MSc, Lemmerick, Yasmin, MBA, Mackey, John R, Prof
Published in The lancet oncology (01.04.2011)
Published in The lancet oncology (01.04.2011)
Get full text
Journal Article